InsidersTradesSigma
申报总数
公司
▲ 买入（1 笔）
▼ 卖出（1 笔）
内部人交易记录
其他已披露买入
1
已披露卖出
1
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Discover the complete record of transactions filed by Pontifax Management 4 G.P. (2015) Ltd.. Director active across 3 companies, notably Eloxx Pharmaceuticals, Inc.. In total, 4 disclosures have been logged. Split: 1 buy · 1 sell. Total volume traded: €36.3m. Activity tracked since 13 May 2021. The latest transaction was disclosed on 15 October 2025 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Pontifax Management 4 G.P. (2015) Ltd.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报4 总计
2,284,612 股@ US$17.75100.0% 占其流量Common Stock, $0.0001 par value per shareSEC:0000921895-25-002765:0
411,681 股Common StockSEC:0001726334-25-000003:0
3,539 股100.0% 占其流量Common StockSEC:0001209191-22-059053:0
1,280,624 股@ US$1.35100.0% 占其流量Common StockSEC:0001104659-21-067336:0
标准退出：2021年8月11日 (T+90)
4 条申报中的 4 条
About Pontifax Management 4 G.P. (2015) Ltd.
Pontifax Management 4 G.P. (2015) Ltd. is a declarant linked to Keros Therapeutics, Inc., LB PHARMACEUTICALS INC, and Eloxx Pharmaceuticals, Inc. It has 4 filings in total, and across the recent sample of 4 filings, the reported amounts are EUR 1431482 of purchases and EUR 34819452 of sales, with the first filing on 2021-05-17 and the last on 2025-10-17. The modal transaction nature is Cession.
